Our medicines
PYRUKYND®
(mitapivat)
U.S. patients and healthcare providers:
Learn more at the PYRUKYND® website or by downloading the full U.S. prescribing information.
EU patients and healthcare providers:
Learn more by downloading the EU Product Information, which includes the summary of product characteristics (SmPC).
AQVESME™
(mitapivat)
U.S. patients and healthcare providers:
Learn more at the AQVESME™ website or by downloading the full U.S. Prescribing Information and Medication Guide.
Patient support
Agios offers the myAgios® patient support services program as a single point of engagement for eligible patients, including access support, prescription fulfillment, financial assistance, disease education and community connections. Patients and their caregivers can enroll in the program to be connected with a dedicated and clinically experienced Patient Support Manager. (U.S. residents only)
Global Managed Access Program
The Agios Global Managed Access Program (GMAP) is aimed at providing access to our approved treatment for patients living in regions where the medicine is not yet widely available.
More
resources
At Agios, people living with rare diseases are at the center of everything we do and every decision we make. Their needs, concerns, input and collaboration are essential to fulfilling our mission: to make a meaningful difference in patients’ lives and fundamentally change the way rare diseases are treated.
If you or a loved one are living with a rare disease, explore more about the ways we can partner together.
For physicians
We recognize and appreciate the significant role that physicians play in the lives of people with rare diseases. They are a cornerstone of the community that treats and supports patients.
With medical information, grant opportunities, educational resources and treatment options, we aim to further their efforts on behalf of patients.